BullFrog AI to Discuss Findings from its Collaboration with Lieber Institute for Brain Development in Fireside Chat Hosted by RedChip
February 09 2024 - 8:00AM
BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or
the "Company"), a technology-enabled drug development company using
artificial intelligence (AI) and machine learning to enable the
successful development of pharmaceuticals and biologics, today
announced its CEO, Vin Singh, alongside distinguished guest,
Daniel R. Weinberger, M.D., Director and CEO of the Lieber
Institute for Brain Development (LIBD), will participate in a
fireside chat hosted by RedChip Companies on March 5, 2024 at 4:15
p.m. ET.
The fireside chat will delve into the early
findings from BullFrog AI and LIBD’s collaboration which
successfully stratified brain expression data, offering what may
turn out to be unprecedented insights into psychiatric
conditions.
This collaborative effort marks a pivotal moment
in psychiatric research, utilizing over 2,800 brain samples to
explore schizophrenia, bipolar disorder, major depressive disorder,
and control groups through advanced graph analytics. For the first
time, this partnership has enabled the clustering of subjects based
on biological data alone, independent of their behavioral
diagnoses. This innovative method has uncovered biological
differences and similarities across various brain disorders and has
identified potential biological subtypes within individual
disorders. These findings have the potential to not only enhance
our understanding of psychiatric conditions but also lay the
groundwork for developing more targeted, effective treatments and
open the door to prospective revenue-generating partnerships with
pharmaceutical companies.
To participate in the fireside chat, please
register at:
https://redchip.zoom.us/webinar/register/WN_gQX4Kwx5RSG0mQyjV80RMw
The fireside chat will include a live Q&A
session. Questions can also be pre-submitted to
rob@redchip.com.
About the Lieber Institute for Brain
Development (LIBD)
The mission of the Lieber Institute for
Brain Development and the Maltz Research Laboratories is to
translate the understanding of basic genetic and molecular
mechanisms of schizophrenia and related developmental brain
disorders into clinical advances that change the lives of affected
individuals. LIBD is an independent, not-for-profit 501(c)(3)
organization and a Maryland tax-exempt medical research institute.
The Lieber Institute’s brain repository of more than 4,000 human
brains is the largest collection of postmortem brains for the study
of neuropsychiatric disorders in the world.
About BullFrog AI
BullFrog AI is a technology-enabled drug
development company using Artificial Intelligence and machine
learning to enable the successful development of pharmaceuticals
and biologics. Through its collaborations with leading research
institutions, BullFrog AI is at the forefront of AI-driven drug
development using its proprietary bfLEAP™ artificial intelligence
platform to create and analyze networks of biological, clinical,
and real-world data spanning from early discovery to late-stage
clinical trials. BullFrog AI is deploying bfLEAP™ for use at
several critical stages of development with the intention of
streamlining data analytics in therapeutics development, decreasing
the overall development costs by decreasing failure rates for new
therapeutics.
For more information visit BullFrog AI at:
Website: https://bullfrogai.com
LinkedIn: https://www.linkedin.com/company/bullfrogai/
Safe Harbor Statement
This press release contains forward-looking
statements. We base these forward-looking statements on our
expectations and projections about future events, which we derive
from the information currently available to us. Such
forward-looking statements relate to future events or our future
performance, including: our financial performance and projections;
our growth in revenue and earnings; and our business prospects and
opportunities. You can identify forward-looking statements by those
that are not historical in nature, particularly those that use
terminology such as "may," "should," "expects," "anticipates,"
"contemplates," "estimates," "believes," "plans," "projected,"
"predicts," "potential," or "hopes" or the negative of these or
similar terms. In evaluating these forward-looking statements, you
should consider various factors, including: our ability to change
the direction of the Company; our ability to keep pace with new
technology and changing market needs; and the competitive
environment of our business. These and other factors may cause our
actual results to differ materially from any forward-looking
statement. Forward-looking statements are only predictions. The
forward-looking events discussed in this press release and other
statements made from time to time by us or our representatives, may
not occur, and actual events and results may differ materially and
are subject to risks, uncertainties, and assumptions about us. We
are not obligated to publicly update or revise any forward-looking
statement, whether as a result of uncertainties and assumptions,
the forward-looking events discussed in this press release and
other statements made from time to time by us or our
representatives might not occur.
Contact:
InvestorsDave GentryRedChip Companies,
Inc.BFRG@redchip.com800-733-2447
SOURCE: BullFrog AI Holdings,
Inc.
Bullfrog AI (NASDAQ:BFRGW)
Historical Stock Chart
From Oct 2024 to Nov 2024
Bullfrog AI (NASDAQ:BFRGW)
Historical Stock Chart
From Nov 2023 to Nov 2024